News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
501,275 Results
Type
Article (31153)
Company Profile (128)
Press Release (469994)
Multimedia
Podcasts (93)
Webinars (12)
Section
Business (159136)
Career Advice (1684)
Deals (25580)
Drug Delivery (95)
Drug Development (60679)
Employer Resources (115)
FDA (11292)
Job Trends (11162)
News (262352)
Policy (24016)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (3)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (1683)
Academic (1)
Accelerated approval (5)
Adcomms (13)
Allergies (59)
Alliances (42049)
ALS (71)
Alzheimer's disease (996)
Antibody-drug conjugate (ADC) (93)
Approvals (11320)
Artificial intelligence (210)
Autoimmune disease (17)
Automation (13)
Bankruptcy (239)
Best Places to Work (8575)
BIOSECURE Act (13)
Biosimilars (80)
Biotechnology (59)
Bladder cancer (62)
Brain cancer (20)
Breast cancer (204)
Cancer (1610)
Cardiovascular disease (141)
Career advice (1434)
Career pathing (27)
CAR-T (89)
Cell therapy (301)
Cervical cancer (14)
Clinical research (49747)
Collaboration (709)
Compensation (237)
Complete response letters (18)
COVID-19 (1805)
CRISPR (34)
C-suite (181)
Cystic fibrosis (66)
Data (1648)
Decentralized trials (2)
Denatured (29)
Depression (27)
Diabetes (213)
Diagnostics (4107)
Digital health (10)
Diversity (4)
Diversity, equity & inclusion (33)
Drug discovery (100)
Drug pricing (95)
Drug shortages (26)
Duchenne muscular dystrophy (74)
Earnings (66947)
Editorial (36)
Employer branding (14)
Employer resources (102)
Events (76821)
Executive appointments (584)
FDA (12178)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (498)
Gene editing (75)
Generative AI (22)
Gene therapy (247)
GLP-1 (576)
Government (2967)
Grass and pollen (5)
Guidances (45)
Healthcare (12000)
Huntington's disease (14)
IgA nephropathy (17)
Immunology and inflammation (90)
Indications (26)
Infectious disease (1893)
Inflammatory bowel disease (108)
Inflation Reduction Act (10)
Influenza (33)
Intellectual property (78)
Interviews (292)
IPO (11466)
IRA (43)
Job creations (2988)
Job search strategy (1214)
Kidney cancer (8)
Labor market (26)
Layoffs (312)
Leadership (15)
Legal (6063)
Liver cancer (42)
Lung cancer (233)
Lymphoma (110)
Machine learning (3)
Management (38)
Manufacturing (261)
MASH (57)
Medical device (7456)
Medtech (7461)
Mergers & acquisitions (14540)
Metabolic disorders (543)
Multiple sclerosis (58)
NASH (17)
Neurodegenerative disease (61)
Neuropsychiatric disorders (17)
Neuroscience (1391)
NextGen: Class of 2025 (4265)
Non-profit (2940)
Northern California (1768)
Now hiring (11)
Obesity (287)
Opinion (201)
Ovarian cancer (50)
Pain (80)
Pancreatic cancer (52)
Parkinson's disease (106)
Partnered (14)
Patents (178)
Patient recruitment (70)
Peanut (26)
People (43476)
Pharmaceutical (67)
Pharmacy benefit managers (15)
Phase I (14514)
Phase II (21429)
Phase III (17585)
Pipeline (1008)
Policy (127)
Postmarket research (2217)
Preclinical (6245)
Press Release (44)
Prostate cancer (92)
Psychedelics (21)
Radiopharmaceuticals (205)
Rare diseases (298)
Real estate (4282)
Recruiting (46)
Regulatory (16517)
Reports (27)
Research institute (1618)
Resumes & cover letters (248)
Rett syndrome (2)
RNA editing (3)
RSV (24)
Schizophrenia (59)
Series A (87)
Series B (47)
Service/supplier (6)
Sickle cell disease (52)
Southern California (1639)
Special edition (12)
Spinal muscular atrophy (113)
Sponsored (21)
Startups (2492)
State (2)
Stomach cancer (10)
Supply chain (50)
Tariffs (33)
The Weekly (62)
United States (16359)
Vaccines (468)
Venture capitalists (24)
Weight loss (189)
Women's health (23)
Worklife (12)
Date
Today (46)
Last 7 days (503)
Last 30 days (1729)
Last 365 days (24418)
2025 (7752)
2024 (25809)
2023 (28730)
2022 (37453)
2021 (39578)
2020 (38305)
2019 (32409)
2018 (24515)
2017 (24367)
2016 (23789)
2015 (27575)
2014 (23027)
2013 (20068)
2012 (20617)
2011 (20550)
2010 (19252)
Location
Africa (678)
Alabama (42)
Alaska (5)
Arizona (118)
Arkansas (9)
Asia (31814)
Australia (4820)
California (4112)
Canada (1477)
China (396)
Colorado (209)
Connecticut (201)
Delaware (105)
Europe (69242)
Florida (712)
Georgia (144)
Idaho (28)
Illinois (387)
India (24)
Indiana (252)
Iowa (3)
Japan (135)
Kansas (75)
Kentucky (18)
Louisiana (5)
Maine (27)
Maryland (608)
Massachusetts (3270)
Michigan (143)
Minnesota (237)
Missouri (47)
Montana (14)
Nebraska (14)
Nevada (39)
New Hampshire (31)
New Jersey (1369)
New Mexico (15)
New York (1227)
North Carolina (779)
North Dakota (4)
Northern California (1768)
Ohio (125)
Oklahoma (11)
Oregon (25)
Pennsylvania (999)
Puerto Rico (8)
Rhode Island (26)
South America (951)
South Carolina (14)
Southern California (1639)
Tennessee (83)
Texas (614)
Utah (128)
Virginia (119)
Washington D.C. (50)
Washington State (379)
West Virginia (2)
Wisconsin (36)
501,275 Results for "gan and lee pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
March 11, 2025
·
4 min read
Pharm Country
Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association’s 84th Scientific Sessions
Gan & Lee Pharmaceuticals announced the presentation of three abstracts featuring their investigational products at the American Diabetes Association’s 84th Scientific Sessions.
June 17, 2024
·
3 min read
Pharm Country
Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association’s 84th Scientific Sessions
Gan & Lee Pharmaceuticals announced the results of the Phase 1b/2a clinical study of the Company’s independently developed glucagon-like peptide-1 receptor agonist, GZR18 Injection, in an obese/overweight population in China, along with the results of two other innovative insulins’ preclinical studies in poster presentations at the American Diabetes Association’s（ADA’s）84th Scientific Sessions.
June 22, 2024
·
7 min read
Press Releases
ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
November 11, 2024
·
5 min read
Press Releases
Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
December 18, 2024
·
4 min read
Press Releases
Gan & Lee Pharmaceuticals’ Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies
October 15, 2024
·
8 min read
Press Releases
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
November 12, 2024
·
4 min read
Press Releases
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
September 16, 2024
·
6 min read
Press Releases
Gan & Lee Pharmaceuticals’ Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
July 22, 2024
·
4 min read
Press Releases
Biocom California Recognizes Akilah Weber Pierson and Kent Lee as Elected Officials of the Year
March 3, 2025
·
3 min read
1 of 50,128
Next
